SG/PUT/ELI LILLY & CO/700/0.01/20.09.24 Stock

DE000SU6VLW7

Real-time Boerse Frankfurt Warrants 07:07:02 2024-07-03 EDT
0.027 ^EUR	-10.00%

Current month	+11.11%
1 month	-72.73%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ELI LILLY AND COMPANY

Chart SG/PUT/ELI LILLY & CO/700/0.01/20.09.24

Latest news about ELI LILLY AND COMPANY

Stocks Edge Up Pre-Bell Ahead of Several Key Economic Reports; Asia, Europe Rise	07:10am	MT
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Wednesday; Tesla to Advance, Reddit to Decline	06:49am	MT
Goldman Sachs Adjusts Price Target on Eli Lilly & Co. to $793 From $785, Maintains Neutral Rating	05:41am	MT
Jefferies Adjusts Price Target on Eli Lilly & Co. to $1,041 From $1,015, Maintains Buy Rating	05:41am	MT

More news

Quotes 5-day view

Date	Price	Change
24-07-03	0.027	-10.00%
24-07-02	0.03	+25.00%
24-07-01	0.024	-11.11%
24-06-28	0.027	-6.90%
24-06-27	0.029	-6.45%

Real-time Boerse Frankfurt Warrants

Last update July 03, 2024 at 07:07 am

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	ELI LILLY AND COMPANY
Issuer	Société Générale
WKN	SU6VLW
ISIN	DE000SU6VLW7
Date issued	2024-01-10
Strike	700 $
Maturity	2024-09-20 (80 Days)
Parity	100 : 1
Emission price	0.92 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.98 €
Lowest since issue	0.023 €
Delta	-0.05x
Omega	13.20
Premium	23.17x
Gearing	271.94x
Moneyness	0.7720
Difference Strike	-206.7 $
Difference Strike %	-29.53%
Spread	0.01 €
Spread %	27.78%
Theoretical value	0.0320
Implied Volatility	36.83 %
Total Loss Probability	93.09 %
Intrinsic value	0.000000
Present value	0.0320
Break even	696.56 €
Theta	-0.01x
Vega	0x
Rho	-0x

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Sector

More about the company